Advanced Solid Tumors Archives

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

January 31, 2024January 31, 2024

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the U.S. Food and Drug Administration…

OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer

November 29, 2023November 29, 2023

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced the dosing…